ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/menin-MLL1-inhibitor
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/menin-MLL1-inhibitor
7
trial(s) found.
NCT07211958
Haem
Phase 3
Recruiting
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Revumenib in Combination With Intensive Chemotherapy in Participants With Newly Diagnosed AML With an NPM1 Mutation (
REVEAL-ND-NPM1
)
menin-MLL1 inhibitor
placebo
Acute myeloid leukaemia
NSW
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2500 - Wollongong - Wollongong Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
WA
6000 - Perth - Royal Perth Hospital
6009 - Nedlands - Linear Clinical Research
NCT07155226
Haem
Phase 1 / Phase 2
Recruiting
A Modular Phase I/II, Open-label, Multi-Centre Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression (
MOMENTUM
)
menin-MLL1 inhibitor
Acute lymphoblastic leukaemia
Acute myeloid leukaemia
Myelodysplastic syndrome
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
WA
6000 - Perth - Royal Perth Hospital
NCT07007312
Haem
Phase 3
Recruiting
Phase 3 Randomized, Double-blind, Placebo-controlled Studies Assessing Ziftomenib in Combination With Either Standard of Care Nonintensive (Venetoclax+Azacitidine) or Intensive (7+3) Therapy in Patients With Untreated NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia (
KO-MEN-017
)
Bcl2 inhibitor
DNA methyltransferase inhibitor
antimetabolite
menin-MLL1 inhibitor
placebo
Acute myeloid leukaemia
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06652438
Haem
Phase 3
Recruiting
Randomized Study to Assess Revumenib in Combination With Azacitidine + Venetoclax in Adult Patients With Newly Diagnosed NPM1-mutated or KMT2A-rearranged AML Ineligible for Intensive Chemotherapy (
HO177
)
Bcl2 inhibitor
DNA methyltransferase inhibitor
antimetabolite
menin-MLL1 inhibitor
Acute myeloid leukaemia
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3168 - Clayton - Monash Medical Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4575 - Birtinya - Sunshine Coast University Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6150 - Murdoch - Fiona Stanley Hospital
NCT04065399
Haem
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Open-label, Dose-Escalation and Dose-Expansion Cohort Study of SNDX-5613 in Patients With Relapsed/Refractory Leukemias, Including Those Harboring an MLL/KMT2A Gene Rearrangement or Nucleophosmin 1 (NPM1) Mutation (
AUGMENT-101
)
menin-MLL1 inhibitor
Acute lymphoblastic leukaemia
Acute myeloid leukaemia
Leukaemia
Mixed phenotype acute leukaemia
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
ACTRN12625000964415
Haem
Phase 3
Not yet recruiting
ALLG AMLM30/EVOLVE II: Randomised study to assess revumenib in combination with azacitidine + venetoclax in adult patients with newly diagnosed NPM1-mutated or KMT2A-rearranged AML ineligible for intensive chemotherapy (
EVOLVE-II
)
Bcl2 inhibitor
DNA methyltransferase inhibitor
antimetabolite
menin-MLL1 inhibitor
Acute myeloid leukaemia
Cancer
ACTRN12622000582752
Haem
Phase 1 / Phase 2
Recruiting
AMLM26/T4- INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in Acute Myeloid Leukaemia (AML)): A Multi-arm, Precision-based, Recursive, Platform Trial - SNDX5613 (
AMLM26-T4
)
menin-MLL1 inhibitor
Acute myeloid leukaemia
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3004 - Melbourne, Southbank - Alfred Health
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3168 - Clayton - Monash Medical Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
4215 - Southport - Gold Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6150 - Murdoch - Fiona Stanley Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (6)
Not yet recruiting (1)
Recruitment Country and State
VIC (6)
WA (6)
NSW (5)
QLD (3)
SA (2)
Phase
Phase 1 / Phase 2 (3)
Phase 3 (4)
Trial Type
Haem (7)
Cancer Therapy Class
KMT2A
100%
menin-MLL1
100%
menin
100%
Bcl2
43%
DNA methyltransferase
43%
Facility
3004 - Melbourne, Southbank - Alfred Health (4)
6150 - Murdoch - Fiona Stanley Hospital (3)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (3)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (3)
6000 - Perth - Royal Perth Hospital (2)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (2)
3168 - Clayton - Monash Medical Centre (2)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (2)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (2)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (1)
2500 - Wollongong - Wollongong Hospital (1)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (1)
6009 - Nedlands - Linear Clinical Research (1)
3065 - Fitzroy - St Vincent's Hospital Melbourne (1)
3128 - Box Hill - Box Hill Hospital - Eastern Health (1)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (1)
4575 - Birtinya - Sunshine Coast University Hospital (1)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (1)
3000 - Melbourne - Peter MacCallum Cancer Centre (1)
2050 - Camperdown - Chris O'Brien Lifehouse (1)
2139 - Concord - Concord Repatriation General Hospital (1)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (1)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (1)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (1)
4102 - Woolloongabba - Princess Alexandra Hospital (1)
4215 - Southport - Gold Coast University Hospital (1)
Cancer Type
Acute myeloid leukaemia
Cancer
Haematological malignancy
Leukaemia
Myeloid leukaemia
Acute lymphoblastic leukaemia
Lymphoid leukaemia
Myelodysplastic syndrome
Myeloproliferative neoplasm
Mixed phenotype acute leukaemia
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy